Table 3.
Significant parameters of the analysis.
| Study Refs. | Δ-FFM (%) | Δ-FM (%) | Δ-C-LDL (mmol/L) | HbA1c (%) | IGF-1 (μg/L) | I (μIU/mL) | T (mmol/L) |
|---|---|---|---|---|---|---|---|
| Elbornsson M. et al. [16] | - | - | -17.5%** | - | +226.59%** | - | - |
| Filipsson Nyström H. et al. [10] | - | +0.25% | -3.57% | +0.21%* | -33.46% | ||
| Beauregard C. et al. [17] | +0.03% | -14.17%* | -0.33% | - | - | +10.30% | -30.00% |
| Cenci MC. et al. [49] | - | - | - | - | - | -46.86% | -24.11% |
| Fideleff HL. et al.[18] | +2.49% | -4.97% | -5.97% | - | - | - | +6.39% |
| Joaquin C. et al. [19] | +1.35% | -3.91% | - | 0.00% | +432.67%** | +58.72%* | +41.70% |
| Setola E. et al.[33] | +5.36%** | -3.51% | -10.21%** | +8.16%* | +117.34%** | -21.11% | +24.14% |
| Oliveira JL. et al. [14] | - | - | decrease*(a) | -9.34% | +270.00%** | -10.69%* | -18.35% |
| Yuen KC. et al. [50]/ group 1 (Low GH dose) | decrease(a) | decrease*(a) | - | - | +229.70%** | - | - |
| Yuen KC. et al. [50]/ group 2 (Standard GH dose) | increase*(a) | decrease*(a) | - | - | +270.31%** | - | - |
| Chihara K. et al. [51] | +4.30*% | -7.85%* | -12.60%** | - | +410.97%** | - | - |
| Bollerslev J. et al. [15] | increase(a) | decrease(a) | -14.82%** | - | - | - | +22.70%* |
| Yuen KC. et al. [52] / group 1 (GH treatment 12 months) | -0.68% | -2.40% | 0.00% | - | +127.60%** | -0.20% | -0.30% |
| Yuen KC. et al. [52] / group 2 (Discontinuation 6 months) |
0.51% | -5.38% | +6.67% | - | +253.90%** | +0.10% | -0.20% |
| Hana V. et al. [53] | - | - | +4.10% | 0.00% | +137.57%** | 0.00% | -11.25% |
| Smith JC. et al. [54] | - | - | -16.67%* | - | - | - | - |
| Borson-Chazot F. et al. [2] | - | -12.04%* | -5.20% | - | +118.31%** | +17.35% | +4.60% |
| O'Neal DN. et al. [55] | - | +3.08% | -14.71%** | -1.92% | +163.26%** | +38.61%* | +15.38% |
| Cuneo RC. et al. [58]/group 1 (GH 12 months) | increase*(a) | decrease*(a) | -13.16%** | - | +191.00%** | - | 0.00% |
| Cuneo RC. et al. [58]/group 2 (Placebo 6-months + GH 6-months) |
increase*(a) | decrease*(a) | -7.69%* | - | +160.20%** | - | +5.00% |
| Johansson JO. et al. [59] | +5.61%* | -2.07% | - | - | +274.01%** | +38.55%** | +6.25% |
| Weaver JU. et al. [60] | -3.99% | +3.57% | - | - | - | - | - |
* = p<0.05; ** = p<0.001; (a)= absolute values not available in the source data; information derived from a diagram.
Fat mass (FM); fat free mass (FFM); glycated haemoglobin (HbA1c); insulin-like growth factor 1 (IGF-1); insulinaemia (I); triglycerides (T).